Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18389809 | 0.79 | CYP1A2 (0.45) | CHRM1CYP1A2MEN1KMT2A | |
| SCHEMBL8211157 | 0.77 | CHRM1 (0.47) | CHRM1HSD11B1KDM4ECYP2C19ALDH1A1 | |
| SCHEMBL8211156 | 0.77 | CHRM1 (0.47) | CHRM1HSD11B1KDM4ECYP2C19ALDH1A1 | |
| SCHEMBL3478043 | 0.77 | CHRM1 (0.47) | CHRM1HSD11B1KDM4ECYP2C19ALDH1A1 | |
| SCHEMBL8829682 | 0.77 | HPGD (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8829683 | 0.77 | HPGD (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL18713205 | 0.76 | EPHX2 (0.45) | CHRM1CYP2D6 | |
| SCHEMBL19541097 | 0.75 | HPGD (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL19540884 | 0.75 | HPGD (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12141187 | 0.75 | CHRM1 (0.49) | CHRM1HSD11B1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRM1 2165/4885HSD11B1 2562/4885KDM4E 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.